Prognostic value of HLA class I expression in patients with colorectal cancer

Yuji Iwayama¹, Tetsuhiro Tsuruma*,¹, Toru Mizuguchi¹, Tomohisa Furuha¹, Nobuhiko Toyota¹, Masayuki Matsumura¹, Toshihiko Torigoe², Noriyuki Sato² and Koichi Hirata¹

Abstract

Background: Prognostic factors are useful for determination of the therapeutic strategy and follow-up examination after curative operation in cancer treatment. The immunological state of the host can influence the prognosis for cancer patients as well as the features of the cancer. Human lymphocyte antigen (HLA) class I molecules have a central role in the anti-cancer immune system. Therefore, we focused on the HLA class I expression level in cancer cells to investigate its prognostic value in patients with colorectal cancer.

Methods: We reviewed the clinical pathology archives of 97 consecutive patients with stage II colorectal cancer who underwent curative operation at the Sapporo Medical University, Japan, from February 1994 to January 2005. Fifty-six high-risk patients had adjuvant chemotherapy. The cancer cell membrane immunoreactivity level for HLA class I expressed by EMR8-5 was classified into three categories (positive, dull, and negative). In this study, the cases were divided into two groups: "positive" and "dull/negative". HLA class I expression level and clinicopathological parameters were evaluated with the Pearson χ² test. Survival analysis was assessed by the Kaplan-Meier methods, and the differences between survival curves were analyzed using the log-rank test.

Results: Immunohistochemical study of HLA class I revealed the following. There were 51 cases that were positive, 40 were dull, and six negative. The HLA class I expression level had no significant correlation with other clinicopathological parameters, except for gender. Univariate and multivariate analyses related to disease-free survival (DFS) revealed that tumor location, HLA expression level, and venous invasion were significant independent prognostic factors (P < 0.05). The 5-year DFS rates in HLA class I positive group and in the dull/negative group were 89% and 70%, respectively. For high-risk patients with adjuvant chemotherapy, the 5-year DFS rates in the HLA class I positive group and in the dull/negative group were 84% and 68%, respectively. For low-risk patients without the chemotherapy, the 5-year DFS rates in the HLA class I positive group and in the dull/negative group were 100% and 71%, respectively.

Conclusions: Our study concluded that the HLA class I expression level might be a very sensitive prognostic factor in colorectal cancer patients with stage II disease.

Keywords: HLA class I, Colorectal cancer, Prognostic factor, Relapse, Disease-free survival

* Correspondence: tsuruma@sapmed.ac.jp

¹Department of Surgery, School of Medicine, Sapporo Medical University, S1, W16, Chuo-ku, Sapporo, Hokkaido 060-0061, Japan

Full list of author information is available at the end of the article

© 2015 Iwayama et al; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Recently, the number of patients with colorectal cancer is increasing. Colorectal cancer is the third most common cancer and the fourth most frequent cause of cancer death worldwide [1]. In Japan, colorectal cancer is the third leading cause of cancer-related death.

The prognosis is related to many histopathological and clinical parameters, with the most important prognostic factor affecting survival for patients undergoing curative operation being the presence or absence of regional lymph node involvement [2]. Therefore, it is generally recommended that patients with stage III colorectal cancer, which includes regional lymph node metastases, should undergo adjuvant chemotherapy. However, controversy still exists regarding the necessity of adjuvant chemotherapy for node-negative patients with stage II disease [3]. The QUASAR trial demonstrated that adjuvant chemotherapy with fluorouracil/leucovorin (FU/LV) could improve survival of patients with stage II colorectal cancer, although the absolute improvements were small [4]. Pooled analysis (IMPACT B2) of randomized trials comparing groups with adjuvant chemotherapy receiving FU/LV and those with surgery alone demonstrated that there was no significant difference in event-free and overall survival [5]. Meanwhile, O’Connor et al. reported that no 5-year survival benefit from adjuvant chemotherapy was observed for patients with stage II disease, although a benefit was observed for those with stage III disease [6]. In the present situation, adjuvant chemotherapy is conducted for patients categorized into a high-risk group among those with stage II disease on the basis of various histopathological or clinical parameters such as poorly differentiated histology, lymphovascular invasion, perineural invasion, T4 tumor stage, bowel obstruction or perforation, and an elevated preoperative plasma level of carcinoembryonic antigen (CEA) [7]. These parameters are indicated in some guidelines such as the National Comprehensive Cancer Network (NCCN), European Society for Medical Oncology (ESMO), etc. [8], although they are not based on conclusive evidence.

The immune system discriminates between self and nonself, targeting, for example, cancer cells. However, cancer cells can escape from the immune system and grow, metastasize, and finally cause death. One mechanism of the immune escape by cancer development is the downregulation of human lymphocyte antigen (HLA) class I molecules, which are cancer antigen-presenting molecules for cytotoxic T lymphocytes (CTLs) [9-12]. The immune state is of great importance in the prognosis of cancer patients. Therefore, we focused on the HLA class I expression level in cancer cells to investigate its prognostic value in patients with colorectal cancer. Since most anti-HLA class I antibodies recognize the allele-specific native structure of HLA class I molecules, these antibodies have been unable to react with denatured HLA class I molecules in formalin-fixed paraffin-embedded tissue sections. However, we created a novel monoclonal pan-HLA class I antibody, EMR8-5, suitable for the immunostaining of formalin-fixed tissue specimens [13]. Therefore, we are now able to retrospectively investigate HLA class I expression levels in cancer specimens that were surgically resected and stored for a long time.

In this study, we investigated the prognostic value of HLA class I expression in patients with stage II colorectal cancer.

Methods
Patients
The study was approved by the Clinical Institutional Ethical Review Board of the Medical Institute of Bioregulation, Sapporo Medical University, Japan. We reviewed the clinical pathology archives of 97 consecutive patients with stage II (TNM classification [UICC]) colorectal cancer (61 men and 36 women; age range: 31–83 years) who underwent curative operation, defined as the removal of all of the tumoral masses, the absence of microscopic residual tumors, histology-negative resection margins, and lymphadenectomy extended beyond the involved nodes at the postoperative pathologic examination, at the Sapporo Medical University Hospital, Sapporo, Japan, from February 1994 to January 2005. Written informed consent was obtained from each patient according to the guidelines of the Declaration of Helsinki. Fifty-six patients with poorly differentiated histology or positive lymphovascular invasion had adjuvant chemotherapy. These patients were randomly assigned to receive 5-FU plus daily divided dose cisplatin (5-FU, 320 mg/m^2 daily for 21 days; CDDP, 3.5 mg/m^2 daily for 21 days) followed by oral 5-FU (200 mg/body daily for 2 years) or oral 5-FU therapy (200 mg/body daily for 2 years) exclusively as randomized trial [14]. No patients with rectal cancer had radiotherapy. Patients whose medical reports were incomplete were excluded. The median follow-up time was 54 months. Patients’ characteristics were assessed by tumor stage (stage IIA, stage IIB, and stage IIC), age, gender, tumor size, tumor location, histological type, and lymphovascular invasion.

Antibody
The monoclonal anti-pan-HLA class I antibody EMR8-5 was established at our laboratory [13]. This mouse mAb (currently commercially available from Hokudo Co., Ltd., Japan) reacts with extracellular domains of HLA-A^*2402, A^*0101, A^*1101, A^*0201, A^*0207, B^*0702, B^*0801, B^*1501, B^*3501, B^*4001, B^*4002, B^*4006, B^*4403, Cw^*0102, Cw^*0801, Cw^*1202, and Cw^*1502 [15]
and shows strong reactivity in Western blots and conventional light microscopic analysis of formalin-fixed, paraffin-embedded sections.

**Immunohistochemistry**

Immunohistochemical staining with the antibody was performed on formalin-fixed, paraffin-embedded tissues after steam heat-induced epitope retrieval. Subsequent incubations with a secondary biotinylated antibody, avidin-conjugated peroxidase complex, and chromogen were carried out on a Ventana NexES (Ventana Medical Systems, Inc., Tucson, AZ) [16]. Slides were then counterstained with hematoxylin, rinsed, dehydrated through graded alcohols into nonaqueous solution, and coverslipped with mounting media. Positive reactivity to EMR8-5 was confirmed by staining of vascular endothelial cells and lymphocytes in sections of tumor specimens [15].

**Evaluation of HLA class I expression**

The cancer cell membrane immunoreactivity level for HLA class I expressed by EMR8-5 was classified into three categories (positive, dull, and negative). Positive was defined as complete and heterogeneous membrane staining in more than 80% of the tumor cells (Figure 1a). Dull was defined as faint, incomplete, and heterogeneous membrane staining in 20% ~ 80% of the tumor cells (Figure 1b). Negative was defined as membrane staining in less than 20% of the tumor cells (Figure 1c). All specimens were reviewed independently using light microscopy in at least five areas at ×200 magnification by two investigators who were blinded to the clinicopathological data (TT and YI).

**Statistical analysis**

We investigated the relationships between HLA class I expression levels and the other parameters (age, gender, tumor location, tumor size, depth, histological type, lymphovascular invasion, budding, number of lymph nodes analyzed after surgery (<12), HLA class I expression level, and adjuvant chemotherapy) and clinical outcome (disease-free survival: DFS). Some of these parameters (depth, histological type, lymphovascular invasion, budding, number of lymph nodes analyzed after surgery (<12)) were recommended as potential prognostic factors for curatively resected colorectal cancer by ESMO guidelines [8] or NCCN Guidelines Version 2 (2014). Statistical analysis was performed using SPSS Statistics 17.0. Deviation between the HLA class I expression level and clinicopathological parameters was evaluated with the Pearson χ² test. Survival analysis was assessed by the Kaplan-Meier method, and the differences between survival curves were analyzed using the log-rank test. To evaluate the correlations between the survival rate and clinicopathological parameters, univariate and multivariate regression analyses according to the Cox proportional hazards regression model were used. A P value <0.05 was considered to indicate statistical significance.

**Results**

**HLA class I expression level and patient characteristics in patients with stage II colorectal cancer**

Immunohistochemical study of HLA class I in cancer cells revealed the following. There were 51 cases (53%) that were positive, which was defined as complete and heterogeneous membrane staining in more than 80% of the tumor cells, as well as 40 (41%) that were dull, which was defined as faint, incomplete, and heterogeneous membrane staining in 20% ~ 80% of the tumor cells, and six (6%) that were negative, which was defined as membrane staining in less than 20% of the tumor cells. In this study, the cases were divided into two groups, those that were “positive” (n = 51) and those that were “dull and negative” (n = 46). The relationships between HLA class
I expression level and patients’ characteristics, i.e., tumor stage (stage IIA, stage IIB, and stage IIC), age, gender, tumor size, tumor location, histological type, and lymphovascular invasion, were assessed. The HLA class I expression level had no significant correlation with other clinicopathological parameters, except for gender (Table 1).

**Prognostic factors in patients with stage II colorectal cancer**

Univariate analysis related to DFS revealed that the tumor location \( (P = 0.01) \) and HLA class I expression level \( (P = 0.02) \) might be significant prognostic factors among age, gender, tumor location, tumor size, depth, histological type, lymphovascular invasion, budding, number of lymph nodes analyzed, HLA class I expression level, and adjuvant chemotherapy. It also suggested that venous invasion might be a prognostic factor \( (P = 0.05) \). Moreover, multivariate analysis revealed that tumor location, HLA expression level, and venous invasion were significant independent prognostic factors \( (P < 0.05) \) (Table 2).

**HLA class I expression and 5-year DFS**

Univariate and multivariate analyses revealed that the HLA class I expression level might be a useful prognostic factor related to DFS. Therefore, survival analysis was conducted using the Kaplan-Meier method. The 5-year DFS rates in the HLA class I positive group and in the dull and negative (dull/negative) group were 89% and 70%, respectively \( (P = 0.01) \) (Figure 2).

**HLA class I expression and adjuvant chemotherapy**

Fifty-six stage II colorectal cancer patients with poorly differentiated histology or positive lymphovascular invasion had adjuvant chemotherapy. For patients with this

| Table 1 HLA class I expression levels and characteristics of the patients (stage II colorectal cancer) |
|----------------------------------|-----------------|-----------------|-----------------|-----------------|
| Positive \( (n = 51; 53\%) \) | Dull and negative \( (n = 46; 47\%) \) | Total \( (n = 97) \) | \( p \) value |
|----------------------------------|-----------------|-----------------|-----------------|
| **Stage**                        |                 |                 |                 |
| Stage IIA                        | 46 (90)         | 42 (91)         | 88              | 0.54            |
| Stage IIB                        | 2 (4)           | 0 (0)           | 2               |
| Stage IIC                        | 3 (6)           | 4 (9)           | 7               |
| **Age (years)**                  |                 |                 |                 |
| Mean ± SD                        | 64 ± 9.7        | 60 ± 12.3       |                 |
| Range                            | 42 ~ 80         | 31 ~ 83         |                 |
| **Gender—no. of patients (%)**   |                 |                 | 0.03            |
| Male                             | 27 (53\%)       | 34 (74\%)       | 61              |
| Female                           | 24 (47\%)       | 12 (26\%)       | 36              |
| **Diameter of primary tumor (mm)—no. (%)** |                 |                 | 0.87            |
| \( \leq 30 \)                     | 11 (22\%)       | 12 (26\%)       | 23              |
| 31 ~ 50                          | 21 (41\%)       | 17 (37\%)       | 38              |
| \( \geq 51 \)                     | 19 (37\%)       | 17 (37\%)       | 36              |
| **Location—no. of patients (%)** |                 |                 | 0.84            |
| Right                            | 16 (31\%)       | 13 (28\%)       | 29              |
| Left                             | 15 (30\%)       | 16 (35\%)       | 31              |
| Rectum                           | 20 (39\%)       | 17 (37\%)       | 37              |
| **Histological type—no. (%)**    |                 |                 | 0.23            |
| Well/mod                         | 48 (94\%)       | 40 (87\%)       | 88              |
| Por/muc                          | 3 (6\%)         | 6 (13\%)        | 9               |
| **Lymphatic invasion—no. of patients (%)** |                 |                 | 0.55            |
| Negative                         | 45 (88\%)       | 40 (87\%)       | 85              |
| Positive                         | 6 (12\%)        | 6 (13\%)        | 12              |
| **Venous invasion—no. of patients (%)** |                 |                 | 0.33            |
| Negative                         | 44 (86\%)       | 42 (91\%)       | 86              |
| Positive                         | 7 (14\%)        | 4 (9\%)         | 11              |
chemotherapy, the 5-year DFS rates of those with HLA class I positive expression and those with dull/negative expression were compared. The 5-year DFS rates in the HLA class I positive group and in the dull/negative group were 84% and 68%, respectively (Figure 3). The 5-year DFS in patients with HLA dull/negative expression was lower than that of those with HLA positive expression, although there was no significant difference ($P = 0.10$).

On the other hand, no patient with HLA class I positive expression without chemotherapy relapsed, whereas 29% of those with HLA dull/negative expression relapsed. For those without adjuvant chemotherapy, there was a significant difference in 5-year DFS between patients with HLA class I positive expression and dull/negative expression ($P = 0.03$) (Figure 4).

### Table 2 Univariate and multivariate analyses related to disease-free survival in 97 colorectal cancer patients

| Variables                        | Univariate Hazard ratio | $P$ value | Multivariate Hazard ratio | $P$ value |
|----------------------------------|-------------------------|-----------|---------------------------|-----------|
| Age                              | 0.98 (0.94–1.02)        | 0.38      |                           |           |
| Gender (F)                       | 1.42 (0.50–4.04)        | 0.51      |                           |           |
| Tumor location (colon vs rectum) | 4.23 (1.49–12.01)       | 0.01      | 4.11 (1.42–11.91)         | 0.009     |
| Tumor size ($\leq 5$ cm)         | 0.64 (0.24–1.73)        | 0.38      |                           |           |
| Tumor invasion (SI)              | 0.52 (0.12–2.28)        | 0.39      |                           |           |
| Differentiation (por or muc)     | 1.50 (0.20–11.35)       | 0.70      |                           |           |
| Lymphatic invasion (ly0, 1 vs ly2, 3) | 1.10 (0.25–4.83)     | 0.90      |                           |           |
| Venous invasion (v0, 1 vs v2, 3) | 3.10 (1.00–9.56)        | 0.05      | 3.85 (1.15–12.92)         | 0.03      |
| Budding                          | 0.52 (0.19–1.41)        | 0.20      |                           |           |
| Number of lymph nodes analyzed (<12) | 1.32 (0.51–3.43)    | 0.57      |                           |           |
| HLA expression level (dull or negative) | 3.86 (1.26–11.85) | 0.02      | 5.36 (1.68–17.11)         | 0.005     |
| Adjuvant chemotherapy (no)       | 0.82 (0.30–2.22)        | 0.70      |                           |           |

**Discussion**

Prognostic factors are useful for determination of the therapeutic strategy and follow-up examination after curative operation in cancer treatment. There are various reports of clinical and pathological prognostic factors. However, there are few immunological prognostic factors. The immunological state of the host can influence the prognosis for cancer patients as well as the features of the cancer.

HLA class I molecules have a central role in the anticancer immune system, especially as cancer antigen-presenting molecules for CTLs [13]. CTLs can recognize antigenic peptides presented on the cell surface by HLA
patients is speculated to be that the beneficial treatments after recurrence might have more influence on OS than the immunological state in the living body such as the HLA class I expression level.

We have also reported that the HLA class I expression level might be a prognostic factor for other cancers such as osteosarcoma, clear cell renal cell carcinoma, and bladder cancer [15-19]. Tsukahara et al. reported that patients with osteosarcoma highly expressing HLA class I had significantly better OS and DFS than those with HLA class I-negative osteosarcoma [15]. Thus, there might be a difference in the impact of the HLA class I expression level on OS or DFS depending on the cancer. Although most reports, including our study, suggested that downregulation of HLA class I expression level was associated with a poor prognosis, Madjd Z et al. reported that total loss of HLA class I was an independent indicator of good prognosis in breast cancer [20]. They considered that the loss of HLA class I might make the tumors more susceptible to natural killer (NK) killing and result in a better prognostic outcome. It is due to the presence of HLA class I allele-specific killer cell inhibitory receptors (KIRs) on the surface of NK cells. Thus, in the absence of HLA class I expression, this KIRs-mediated inhibitory signaling is lost, resulting in the activation of NK cytolytic effector functions [21]. NK cell-mediated cytotoxicity is regulated by a delicate balance between activating and inhibitory signals. So, the prognostic influence brought by the HLA class I expression level might depend on the various cancer immune circumstances.

Surgery alone has relatively favorable results in colorectal cancer patients with stage II disease; hence, any advantage conferred by adjuvant chemotherapy after the curative operation is likely to be small. However, in real life in Japan, approximately 13% of patients with stage II colorectal cancer are found to have recurrence. The seventh edition of the American Joint Committee on Cancer (AJCC) Staging Manual divides stage II into three groups: stage IIA (T3N0), stage IIB (T4aN0), and stage IIC (T4bN0). There is a report that the prognoses for the stage IIB and IIC subgroups are worse than those of some stage III patients [22]. Therefore, stage II patients could be divided into high- and low-risk populations. We should select high-risk stage II patients and give adjuvant chemotherapy to prevent recurrence by micrometastases only to those patients who can obtain a significant benefit from it. The NCCN Guidelines Version 2 (2014) recommended the following risk factors for recurrence: number of lymph nodes analyzed after surgery (<12), poorly differentiated histology, lymphatic/vascular invasion, bowel obstruction, perineural invasion, localized perforation, and close, indeterminate, or positive margins. The ESMO consensus guideline recommended
the following factors: lymph node sampling <12, poorly differentiated tumor, vascular or lymphatic or perineural invasion, T4 stage, and clinical presentation with intestinal occlusion or perforation [8]. In this study, patients with poorly differentiated tumors or moderate and severe lymphovascular invasion were considered to be high-risk stage II patients and underwent adjuvant chemotherapy. We investigated the 5-year DFS in stage II patients with and without adjuvant chemotherapy, respectively. Patients with HLA class I positive expression had a higher DFS rate than those with HLA class I null/negative expression under both settings. In addition, for low-risk patients without chemotherapy, all patients with HLA class I positive expression did not relapse, although 29% of those with HLA class I null/negative expression relapsed. These data might make certain of the prognostic value of HLA class I expression for relapse.

Conclusions
The HLA class I expression level might be a very sensitive prognostic factor in colorectal cancer patients with stage II disease.

Abbreviations
DFS: Disease-free survival; CEA: Carcinoembryonic antigen; CTLs: Cytotoxic T lymphocytes; ESMO: European Society for Medical Oncology; NCCN: National Comprehensive Cancer Network; NK: Natural killer; KIRs: Killer cell inhibitory receptors; AJCC: American Joint Committee on Cancer.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
YI and TT reviewed all specimens stained with the antibody EMR8-S. TM and TF managed the database of colorectal cancer patients. NT performed the statistical analysis. MM and TT carried out the immunohistochemical staining. NS and KI participated in the design and coordination of this study and helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgements
Emiri Nakazawa and Kumiko Shimozawa provided EMR8-S.

Author details
1. Department of Surgery, School of Medicine, Sapporo Medical University, S1, W16, Chuo-ku, Sapporo, Hokkaido 060-0061, Japan. 2. Department of Pathology, School of Medicine, Sapporo Medical University, S1, W16, Chuo-ku, Sapporo, Hokkaido 060-0061, Japan.

Received: 31 July 2014 Accepted: 8 January 2015
Published online: 12 February 2015

References
1. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal cancer. Lancet. 2005;365:153–65.
2. Ohogawa S, Kudo Y, Tanaka S, Kuwai T, Kimura S, Chayama K. Expression of VEG-F and VEG-FD at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma. Cancer Sci. 2004;95:32–9.
3. Wils J. Adjuvant treatment of colon cancer: past, present and future. J Chemotherapy. 2007;19:115–22.
4. Quasar Collaborative Group, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomized study. Lancet. 2007;370:2020–9.
5. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in 2 colon cancer. J Clin Oncol. 1999;17:1356–63.
6. O’Connor EG, Greenblatt DY, Lo Conte NK, Gangnon RE, Liu JU, Heise CP, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 2011;29:3381–8.
7. Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ. Adjuvant treatment of colorectal cancer. CA Cancer J Clin. 2007;57:168–85.
8. Schnoll SJ, Van Cutsem E, Stein A, Valentin V, Glimelius B, Haustermans K, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 2012;23:2479–516.
9. Marincola FM, Jaffe EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol. 2000;74:181–273.
10. Seliger B, Cabrera T, Garrido F, Ferreres S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol. 2002;12:123–13.
11. Raffaghello L, Prigione I, Airoldi I, Camoriano M, Morandi F, Bocca P, et al. Mechanisms of immune evasion of human neuroblastoma. Cancer Lett. 2005;228:151–6.
12. Lopez-Albaieteta A, Nayak JV, Ogino T, Machandia A, Gooding W, DeLeo AB, et al. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol. 2006;176:3402–9.
13. Torigoe T, Asanuma H, Nakazawa E, Tamura Y, Hirohashi Y, Yamamoto E, et al. Establishment of a monoclonal anti-HLA class I antibody suitable for immunostaining of formalin-fixed tissue: unusually high frequency of down-regulation in breast cancer tissues. Pathol Int. 2012;62:303–8.
14. Hata F, Saiako K, Hirata Y, Yamamitsu S, Shiiasaka T. Efficacy of a continuous versus infusional of fluorouracil and daily divided dose cisplatin as adjuvant therapy in resectable colorectal cancer: a prospective randomized trial. Surg Today. 2008;38:623–32.
15. Tsukahara T, Kawaguchi S, Torigoe T, Asanuma H, Nakazawa E, Shimozawa K, et al. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-HLA class I monoclonal antibody, EMR8-S. Cancer Sci. 2006;97:1374–80.
16. Le Neel T, Moreau A, Laboisse C, Truchaud A. Comparative evaluation of automated systems in immunohistochemistry. Clin Chim Acta. 1998;278:185–92.
17. Kitamura H, Homma I, Torigoe T, Asanuma H, Sato N, Tsukamoto T. Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal cell carcinoma. J Urol. 2007;177:1269–72.
18. Homma I, Kitamura H, Torigoe T, Tanaka T, Sato E, Hirohashi Y, et al. Human leukocyte antigen class I down-regulation in muscle-invasive bladder cancer: its association with clinical characteristics and survival after cystectomy. Cancer Sci. 2009;100:2331–4.
19. Kitamura H, Torigoe T, Homma I, Sato E, Asanuma H, Hirohashi Y, et al. Effects of human leukocyte antigen class I expression of tumor cells on outcome of intravesical instillation of bacillus Calmette-Guerin immunotherapy for bladder cancer. Clin Cancer Res. 2006;12:4641–4.
20. Yabe H, Tsukahara T, Kawaguchi S, Wada T, Torigoe T, Sato N, et al. Prognostic significance of HLA class I expression in Ewing’s sarcoma family of tumors. J Surg Oncol. 2011;103:580–6.
21. Majdz J, Spendlove I, Pinder SE, Ellis IO, Durrant LG. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer. 2005;117:248–55.
22. Watson NF, Ramage JM, Majdz J, Spendlove I, Ellis O, Scholefield JH, et al. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer. 2006;118:16–10.